Establishment of a monoclonal anti-pan HLA class I antibody suitable for immunostaining of formalin-fixed tissue: Unusually high frequency of down-regulation in breast cancer tissues

Pathology International

Volumn 62, Issue 5, 2012, Pages 303-308

  Torigoe, Toshihiko ^a   Asanuma, Hiroko ^b   Nakazawa, Emiri ^c   Tamura, Yasuaki ^a   Hirohashi, Yoshihiko ^a   Yamamoto, Eri ^a   Kanaseki, Takayuki ^a   Hasegawa, Tadashi ^b   Sato, Noriyuki ^a  

^a Departments of Pathology   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Antigen presentation; Beta2 microglobulin; Breast cancer; Immune escape; MHC class I

Indexed keywords

BETA 2 MICROGLOBULIN; EMR8 5 ANTIBODY; FORMALDEHYDE; HLA ANTIBODY; HLA ANTIGEN CLASS 1; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER TISSUE; COLON CANCER; DOWN REGULATION; GENE FREQUENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BETA 2-MICROGLOBULIN; BREAST NEOPLASMS; DOWN-REGULATION; FEMALE; FORMALDEHYDE; GENES, MHC CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; TISSUE FIXATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84860305582     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2012.02789.x     Document Type: Article

References (23)

1. Sato N, Nabeta Y, Kondo H etal. Human CD8 and CD4 T cell epitopes of epithelial cancer antigens. Cancer Chemother Pharmacol 2000; 46 Suppl: S86-90.
2. Kawaguchi S, Wada T, Ida K etal. Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. J Transl Med 2005; 3: 1. doi:10.1186/1479-5876-3-1.
3. Tsuruma T, Hata F, Furuhata T etal. Peptide-based vaccination for colorectal cancer. Expert Opin Biol Ther 2005; 5: 799-807.
4. Tsuruma T, Hata F, Torigoe T etal. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2004; 2: 19-29.
5. Marincola FM, Jaffee EM, Hicklin DJ etal. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181-273.
6. Seliger B, Cabrera T, Garrido F etal. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 2002; 12: 3-13.
7. Raffaghello L, Prigione I, Airoldi I etal. Mechanisms of immune evasion of human neuroblastoma. Cancer Lett 2005; 228: 155-61.
8. Lopez-Albaitero A, Nayak JV, Ogino T etal. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 2006; 176: 3402-9.
9. Sato Y, Sahara H, Tsukahara T etal. Improved generation of HLA class I/peptide tetramers. J Immunol Methods 2002; 271: 177-84.
10. Miyazaki A, Sato N, Takahashi S etal. Cytotoxicity of histocompatibility leukocyte antigen-DR8-restricted CD4 killer T cells against human autologous squamous cell carcinoma. Jpn J Cancer Res 1997; 88: 191-7.
11. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 1986; 137: 2299-306.
12. Stam NJ, Vroom TM, Peters PJ etal. HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol 1990; 2: 113-25.
13. Garrido F, Cabrera T, Accolla RS. HLA and cancer: 12th International Histocompatibility Workshop study. In: Charron D, editor Genetic diversity of HLA Functional and medical implication Proc Twelfth International Histocompatibility Workshop and Conference 1997, Vol. II. France: EDK, Sevres: 445-52.
14. Mattijssen V, De Mulder PH, Schalkwijk L etal. HLA antigen expression in routinely processed head and neck squamous cell carcinoma primary lesions of different sites. Int J Cancer Suppl 1991; 6: 95-100.
15. Kamarashev J, Ferrone S, Seifert B etal. TAP1 down-regulation in primary melanoma lesions: An independent marker of poor prognosis. Int J Cancer 2001; 95: 23-8.
16. Madjd Z, Spendlove I, Pinder SE etal. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 2005; 117: 248-55.
17. Kageshita T, Ishihara T, Campoli M etal. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions. Tissue Antigens 2005; 65: 419-28.
18. Cabrera T, Lara E, Romero JM etal. HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunol Immunother 2007; 56: 709-17.
19. Mizukami Y, Kono K, Maruyama T etal. Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma. Br J Cancer 2008; 99: 1462-7.
20. Morabito A, Dozin B, Salvi S etal. Analysis and clinical relevance of human leukocyte antigen class I, heavy chain, and beta2-microglobulin downregulation in breast cancer. Hum Immunol 2009; 70: 492-5.
21. Bandoh N, Ogino T, Katayama A etal. HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis. Oncol Rep 2010; 23: 933-9.
22. Tanaka K, Tsuchikawa T, Miyamoto M etal. Down-regulation of Human Leukocyte Antigen class I heavy chain in tumors is associated with a poor prognosis in advanced esophageal cancer patients. Int J Oncol 2011; 40: 965-74.
23. Gonzalez-Galarza FF, Christmas S, Middleton D etal. Allele frequency net: A database and online repository for immune gene frequencies in worldwide populations. Nucleic Acid Res 2011; 39: D913-D9.